Evidence map›Paper›PMID 22282482›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2012

Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation.

Michael D Rizzari, Thomas M Suszynski, Kristen J Gillingham, Ty B Dunn, Hassan N Ibrahim, William D Payne, Srinath Chinnakotla, Erik B Finger, David E R Sutherland, Raja Kandaswamy and 5 more

Abstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Trial
  2. Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2013
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Trabecular bone score in kidney transplant recipients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016
    Article
  17. Moving Beyond Minimization Trials in Kidney Transplantation.Journal of the American Society of Nephrology : JASN · 2015
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Michael D RizzariDepartment of Surgery, Division of Transplantation, University of Minnesota, Minneapolis, 55455, USA.
Thomas M Suszynski
Kristen J Gillingham
Ty B Dunn
Hassan N Ibrahim
William D Payne
Srinath Chinnakotla
Erik B Finger
David E R Sutherland
Raja Kandaswamy
John S Najarian
Timothy L Pruett
Aleksandra Kukla
Richard Spong
Arthur J Matas

Funding

Viral Infections and Posttransplant MorbidityP01DK013083 · NIDDK · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MATAS, ARTHUR J · 1986 to 2013
$14.9M
NIDDK NIH HHS DK-13083NIDDK NIH HHS P01 DK013083
6 · The paper itself

Abstract

BACKGROUND AND

objectivesRapid discontinuation of prednisone after kidney transplantation potentially allows for minimization of steroid-related side effects. Although intermediate-term data with rapid discontinuation of prednisone have been promising, concern still exists regarding long-term outcomes. The 10-year experience is reported herein. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Between October 1, 1999 and December 31, 2010, 1241 adult primary kidney transplants (791 living donor and 450 deceased donor) were performed using a protocol in which prednisone is discontinued after postoperative day 5. The 10-year actuarial recipient and graft survival rates and prednisone-related side effects were studied.

resultsTen-year actuarial patient survival was 71% for living donor transplants and 62% for deceased donor transplants; 10-year graft survival was 61% for living donor transplants and 51% for deceased donor transplants, and was comparable to 10-year Scientific Registry of Transplant Recipients national data. Ten-year death-censored graft survival was 79% for living donor transplants and 80% for deceased donor transplants. Ten-year acute rejection rates were 25% for deceased donor transplants and 31% for living donor transplants; 10-year chronic rejection (interstitial fibrosis/tubular atrophy) rates were 39% for deceased donor transplants and 47% for living donor transplants. For nondiabetic recipients of living donor or deceased donor allografts, the incidence of new-onset diabetes was significantly lower than in historical controls on prednisone (P<0.001). We also found significantly reduced rates of cataracts, avascular necrosis, and cytomegalovirus infection in some subgroups.

conclusionsPrednisone-related side effects can be minimized in a protocol incorporating rapid discontinuation of prednisone for maintenance immunosuppression. Ten-year patient and graft outcomes remain acceptable.

Indexed as

Kidney TransplantationAdultDrug Administration ScheduleFemaleGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKaplan-Meier EstimateLiving DonorsMaleMiddle AgedMinnesotaPrednisoneRisk AssessmentRisk FactorsImmunosuppressive AgentsPrednisone

Identifiers

PMID22282482
PMCPMC3302679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.